Clinical Application of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma:Current Status and Challenges
10.13865/j.cnki.cjbmb.2025.06.1529
- VernacularTitle:双特异性抗体在复发/难治性多发性骨髓瘤中的临床应用:现状与挑战
- Author:
Chen-Yun WANG
1
;
Zhen CAI
Author Information
1. 浙江大学医学院附属第一医院骨髓移植中心,杭州 310003
- Publication Type:Journal Article
- Keywords:
relapsed/refractory multiple myeloma(RRMM);
bispecific antibodies(BsAbs);
immuno-therapy
- From:
Chinese Journal of Biochemistry and Molecular Biology
2025;41(8):1096-1105
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma(MM)is a hematologic malignancy originating from plasma cells in the bone marrow.In recent years,the use of novel drugs and hematopoietic stem cell transplantation(HSCT)has significantly improved the prognosis of MM patients.However,MM remains challenging to cure and is prone to relapse and resistance.For patients with relapsed/refractory multiple myeloma(RRMM),there is an urgent need to explore novel therapeutic approaches.Bispecific antibodies(BsAbs)are a promising class of immunotherapeutics that functions by simultaneously binding to tumor cell antigens and endogenous effector cells,thereby forming an immunological synapse.This interaction facilitates the activation of effector cells,leading to the targeted lysis of tumor cells.Numerous clinical studies have demonstrated the significant efficacy of BsAbs,either as monotherapy or in combination with other treatment regimens,in patients with RRMM.This article summarizes the mechanisms of action,ef-ficacy,and safety of BsAbs,and discusses optimal sequencing strategies in immunotherapy,aiming to provide new perspectives for the treatment of MM.
